Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

Five newcos developing iPS cell-derived therapies for cancer

The biotechs are turning iPS cells into NK, T, B cells and macrophages

By Danielle Golovin, Staff Writer
November 4, 2021 1:12 AM UTC

At least five companies launched since 2019 are using induced pluripotent stem (iPS) cells to create immune cell therapies for cancer.

iPS cells can differentiate into any cell type in the body and proliferate indefinitely in culture, offering a potentially limitless source of starting material for the production of homogenous populations of therapeutic cells...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alphageneron Pharmaceuticals Inc.

Beigene Ltd.

Century Therapeutics Inc.

Clade Therapeutics Inc.

Cytovia Therapeutics Inc.

Gilead Sciences Inc.

Kyoto University